CA3244501A1 - Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses - Google Patents
Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their UsesInfo
- Publication number
- CA3244501A1 CA3244501A1 CA3244501A CA3244501A CA3244501A1 CA 3244501 A1 CA3244501 A1 CA 3244501A1 CA 3244501 A CA3244501 A CA 3244501A CA 3244501 A CA3244501 A CA 3244501A CA 3244501 A1 CA3244501 A1 CA 3244501A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/078653 | 2022-03-01 | ||
| CN2022078653 | 2022-03-01 | ||
| CN2022091497 | 2022-05-07 | ||
| CNPCT/CN2022/091497 | 2022-05-07 | ||
| CNPCT/CN2022/127020 | 2022-10-24 | ||
| CN2022127020 | 2022-10-24 | ||
| CNPCT/CN2023/071857 | 2023-01-12 | ||
| CN2023071857 | 2023-01-12 | ||
| PCT/CN2023/078948 WO2023165504A1 (en) | 2022-03-01 | 2023-03-01 | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3244501A1 true CA3244501A1 (en) | 2023-09-07 |
Family
ID=87883011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3244501A Pending CA3244501A1 (en) | 2022-03-01 | 2023-03-01 | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240051958A1 (OSRAM) |
| EP (1) | EP4486741A4 (OSRAM) |
| JP (1) | JP2025508971A (OSRAM) |
| KR (1) | KR20240156394A (OSRAM) |
| CN (1) | CN118871438A (OSRAM) |
| AR (1) | AR128669A1 (OSRAM) |
| AU (1) | AU2023227010A1 (OSRAM) |
| CA (1) | CA3244501A1 (OSRAM) |
| IL (1) | IL315015A (OSRAM) |
| MX (1) | MX2024010648A (OSRAM) |
| TW (1) | TW202342477A (OSRAM) |
| WO (1) | WO2023165504A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| AR131785A1 (es) | 2023-02-06 | 2025-04-30 | Bayer Ag | Combinaciones de inhibidores de dgk (diacilglicerol quinasa) |
| WO2025051110A1 (en) * | 2023-09-04 | 2025-03-13 | Insilico Medicine Ip Limited | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| TW200418829A (en) * | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| EP1613625A1 (en) | 2003-03-14 | 2006-01-11 | AstraZeneca AB | Novel fused triazolones and the uses thereof |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| AR064416A1 (es) * | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
| WO2011075747A1 (en) | 2009-12-18 | 2011-06-23 | Glaxosmithkline Llc | Therapeutic compounds |
| WO2017019723A1 (en) * | 2015-07-29 | 2017-02-02 | Merck Sharp & Dohme Corp. | Aza-cyanoquinolinone pde9 inhibitors |
| CN111406050B (zh) * | 2018-01-17 | 2023-02-03 | 厦门宝太生物科技股份有限公司 | 吲哚胺2,3-双加氧酶抑制剂及其用途 |
| RS64641B1 (sr) | 2018-06-27 | 2023-10-31 | Bristol Myers Squibb Co | Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija |
| US11866430B2 (en) | 2018-06-27 | 2024-01-09 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as T cell activators |
| KR20220029719A (ko) | 2019-07-04 | 2022-03-08 | 리드 파마 홀딩 비.브이. | 에스트로겐-관련 수용체 알파 조절제 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| IL291523B2 (en) | 2019-10-18 | 2023-12-01 | Lead Pharma Holding Bv | Estrogen-related receptor alpha (err-alpha) modulators |
| US20230062100A1 (en) | 2019-11-28 | 2023-03-02 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| US12478621B2 (en) * | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021105116A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| IL294085A (en) | 2019-12-19 | 2022-08-01 | Bristol Myers Squibb Co | Combinations of dgk inhibitors and checkpoint antagonists |
| WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
| MX2022007130A (es) | 2019-12-23 | 2022-07-11 | Bristol Myers Squibb Co | Derivados de piperazina sustituidos utiles como activadores de celulas t. |
| BR112022012220A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| ES3013568T3 (en) * | 2019-12-23 | 2025-04-14 | Bristol Myers Squibb Co | Substituted heteroaryl compounds useful as t cell activators |
| EP4445902A3 (en) | 2019-12-24 | 2024-12-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| CA3202330A1 (en) | 2020-12-16 | 2022-06-23 | Anthony Casarez | Compounds useful as t cell activators |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117836296A (zh) | 2021-08-03 | 2024-04-05 | 百济神州有限公司 | 吡唑并吡啶酮化合物 |
| WO2023165525A1 (en) | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023165528A1 (en) | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| EP4486745A4 (en) | 2022-03-01 | 2026-03-11 | Insilico Medicine Ip Ltd | Diacylglycerol Kinase (DGK) Alpha Inhibitors and Their Uses |
| WO2023184327A1 (en) | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| JP2025510945A (ja) | 2022-03-31 | 2025-04-15 | インベンティスバイオ カンパニー リミテッド | キナーゼ阻害剤、その製造方法および用途 |
-
2023
- 2023-03-01 IL IL315015A patent/IL315015A/en unknown
- 2023-03-01 JP JP2024552216A patent/JP2025508971A/ja active Pending
- 2023-03-01 KR KR1020247032094A patent/KR20240156394A/ko active Pending
- 2023-03-01 CN CN202380024550.4A patent/CN118871438A/zh active Pending
- 2023-03-01 EP EP23762903.5A patent/EP4486741A4/en active Pending
- 2023-03-01 AR ARP230100509A patent/AR128669A1/es unknown
- 2023-03-01 WO PCT/CN2023/078948 patent/WO2023165504A1/en not_active Ceased
- 2023-03-01 TW TW112107272A patent/TW202342477A/zh unknown
- 2023-03-01 CA CA3244501A patent/CA3244501A1/en active Pending
- 2023-03-01 AU AU2023227010A patent/AU2023227010A1/en active Pending
- 2023-10-13 US US18/486,374 patent/US20240051958A1/en active Pending
- 2023-11-13 US US18/507,595 patent/US12077538B2/en active Active
-
2024
- 2024-08-29 MX MX2024010648A patent/MX2024010648A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025508971A (ja) | 2025-04-10 |
| EP4486741A4 (en) | 2026-04-08 |
| IL315015A (en) | 2024-10-01 |
| CN118871438A (zh) | 2024-10-29 |
| EP4486741A1 (en) | 2025-01-08 |
| WO2023165504A1 (en) | 2023-09-07 |
| US20240051958A1 (en) | 2024-02-15 |
| MX2024010648A (es) | 2024-11-08 |
| TW202342477A (zh) | 2023-11-01 |
| KR20240156394A (ko) | 2024-10-29 |
| AU2023227010A1 (en) | 2024-09-12 |
| US12077538B2 (en) | 2024-09-03 |
| US20240116935A1 (en) | 2024-04-11 |
| AR128669A1 (es) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI912127B (zh) | KRas G12D抑制劑 | |
| CA3226720A1 (en) | Kras g12d inhibitors and uses thereof | |
| JP7592220B2 (ja) | アゼチジン及びピロリジンｐａｒｐ１阻害剤及びその使用 | |
| US12077538B2 (en) | Diacylglycerol kinase (DGK) alpha inhibitors and uses thereof | |
| CA2971640A1 (en) | Cot modulators and methods of use thereof | |
| JP7686755B2 (ja) | 三環式化合物とその用途 | |
| IL314084A (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| WO2023165525A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| JP2023508858A (ja) | トリアゾロピリダジン系誘導体、その調製方法、医薬組成物及び使用 | |
| JP2024540935A (ja) | メチオニンアデノシルトランスフェラーゼ２ａ（ｍａｔ２ａ）阻害剤およびその使用 | |
| TW202521544A (zh) | TNFα活性調節劑及其用途 | |
| CN115043836B (zh) | 一种咪唑并吡啶衍生物的p2x3受体选择性调节剂及其药物用途 | |
| US20250214990A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| TW202412760A (zh) | Cbl-b抑制劑及其使用方法 | |
| WO2023165528A1 (en) | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof | |
| CN120535527A (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
| WO2023241627A1 (en) | Cdk8/19 dual inhibitors and methods of use thereof | |
| CN121941684A (zh) | Cbl-b抑制剂及其使用方法 | |
| TW202513069A (zh) | 作為週期蛋白依賴性激酶抑制劑之胺基嘧啶衍生物 | |
| IL325314A (en) | Tyk2 inhibitors, compositions and methods thereof | |
| TW202434215A (zh) | 螺環hpk1拮抗劑及其用途 | |
| EA052540B1 (ru) | Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения | |
| HK40117800A (zh) | 二酰基甘油激酶(DGK)α抑制剂及其用途 | |
| WO2025261355A1 (en) | Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof | |
| WO2025051110A1 (en) | Combinations treatments of diacylglycerol kinase (dgk) alpha inhibitors and other therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240816 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20240822 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240822 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240822 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250214 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250214 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250214 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260226 |